Table 4.
Relative risk (95% CI) of diabetes developing within 4 years of non-diabetic subjects (n = 1,163) over the cutoff values of AhRL or MIS-ATP.
| Total | Male | Female | ||||
|---|---|---|---|---|---|---|
| AhRL (pM) | <2.70 | ≥2.70 | <2.70 | ≥2.70 | <2.70 | ≥2.70 |
| Total cases | 892 | 271 | 376 | 127 | 516 | 144 |
| Newly developed diabetes (%) | 19 (2.1%) | 50 (18.5%) | 9 (2.4%) | 31 (24.4%) | 10 (1.9%) | 19 (13.2%) |
| Model A | 1 | 10.40 (6.01‒17.99) | 1 | 13.17 (6.06‒28.59) | 1 | 7.69 (3.49‒16.95) |
| Model B | 1 | 10.57 (6.05‒18.48) | 1 | 14.11 (6.44‒30.95) | 1 | 7.11 (3.14‒16.08) |
| Model C | 1 | 9.40 (5.32‒16.61) | 1 | 14.15 (6.27‒31.90) | 1 | 6.02 (2.62‒13.84) |
| Model D | 1 | 7.60 (4.23‒13.64) | 1 | 12.66 (5.42‒29.60) | 1 | 4.45 (1.89‒10.47) |
| MIS-ATP (%) | > 88.1 | ≤88.1 | >88.1 | ≤88.1 | >88.1 | ≤88.1 |
| Total cases | 721 | 442 | 313 | 190 | 408 | 252 |
| Newly developed diabetes (%) | 18 (2.5%) | 51 (11.5%) | 10 (3.2%) | 30 (15.8%) | 8 (2.0%) | 21 (8.3%) |
| Model A | 1 | 5.09 (2.94–8.84) | 1 | 5.68 (2.70–11.92) | 1 | 4.55 (1.98–10.43) |
| Model B | 1 | 4.90 (2.81–8.55) | 1 | 5.54 (2.63–11.68) | 1 | 4.11 (1.76–9.59) |
| Model C | 1 | 4.71 (2.68–8.29) | 1 | 5.61 (2.62–12.00) | 1 | 3.91 (1.66–9.22) |
| Model D | 1 | 4.27 (2.38–7.64) | 1 | 6.07 (2.70–13.48) | 1 | 3.03 (1.25–7.35) |
Model A: unadjusted. Model B: sex, age, smoking. Model C: model B + waist circumference and systolic BP-adjusted. Model D: model C + fasting glucose and triglyceride-adjusted. AhRL is expressed as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) equivalents (TCDDeq, pM). MIS-ATP is expressed as % of the 10% charcoal-stripped human serum (CSS)-treated control.